Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of$ 0.19. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of$ 0.25 per share when it actually produced a loss of $0.21, delivering a surprise of 16%.Over the last four quarters, the c ...